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The objetive of this study was to compare a single dose of secnidazole 
versus multiple doses of fenbendazole for the treatment of dogs with 
asymptomatic Giardia infection. Materials and methods: Twenty-four as-
ymptomatic dogs with a positive test result for Giardia spp were random-
ized in two equal groups to receive a single dose of secnidazole at 30 mg/
kg PO, or fenbendazole at 50 mg/ kg PO q24h for 3 days. Hematological 
parameters were evaluated before and 8 days after treatment, and feces 
were re-examined at days 8, 15, and 30 post-treatment by fecal flotation 
and antigen test. Results: The number of positive dogs in the fenben-
dazole group was: 1 (day 8) and 3 (days 15 and 30). In the secnidazole 
group, the number of positive cases were: 4 (day 8), 3 (day 15), and 1 (day 
30). Conclusion: Treatment with secnidazole or fenbendazole, were effec-
tive between 75% and 92% to eliminate the excretion of Giardia cysts in 
canines together with hygienic measures to control, like disinfection with 
quaternary ammonium of patients and their environment. Further studies 
that include more animals and multiple fecal exams on consecutive days 
would be necessary to confirm its efficacy in dogs.
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1. Introduction
Giardia spp are flagellated protozoan parasites found in the intestinal tract of mammals, birds, and reptiles worldwide.  Giardia duodenalis (syn. 
G. intestinalis or G. lamblia) inhabits the small intestine 
of humans, dogs, and cats, and is considered as a potential 
zoonotic risk [1]. In developing countries with a high preva-
lence and incidence of infection, some studies suggest that 
chronic Giardiasis causes delayed growth in children  [2,3,4].
Although Giardia infection may be common, clinical 
signs of diarrhea are not always present and many dogs 
and cats are subclinical carriers [5,6,7]. The prevalence in 
dogs has been reported to vary from 1% to nearly 28%, 
with some predisposing factors being age and lack of hy-
gienic conditions [8,9].  Although G. intestinalis is a species 
complex with a wide mammalian host range, including 
people, the role of pets as a source of human Giardiasis 
remains unclear and there are no current recommendations 
to test and treat healthy pets for Giardia spp infection [1,2,10]. 
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However, animals housed under conditions of stress or 
overcrowding may have high prevalences of Giardia, for 
this reason it is necessary to treat the infected animals in 
all cases.
Treatment of Giardiasis with fenbendazole at 50 mg/
kg orally every 24 hours for 3–5 days has been reported to 
effectively eliminate infections in 86%–100% of dogs and 
cats [11,12]. An alternative treatment is metronidazole at 50 
mg/kg q24h for 5 days, but it is only about 67% effective 
in eliminating Giardia spp from infected dogs and may 
be associated with adverse side effects such as develop-
ment of anorexia and vomiting, which may progress to 
neurotoxicosis [13,14]. In addition, treatment for 5 days is 
impractical for some animals that are difficult to handle 
or for treating large populations (e.g., kennels, catteries). 
In these situations, the search for alternative therapeutic 
options, including single-dose treatments, could be quite 
valuable.
Secnidazole is an antiparasitic used in humans that it 
is administered as a single dose for the control and treat-
ment of Giardiasis [15,16].  When a single oral dose of 30 
mg/kg was used extralabel in 18 naturally infected cats it 
achieved a 100% efficacy to eliminate cyst shedding in 
the feces [17]. The aim of this study was to evaluate the use 
of a similar single oral dose of secnidazole for treating 
naturally acquired Giardiasis in dogs.
2. Materials and Methods
2.1 Ethics Committee
This study was approved by the Ethics Committee for 
Animal Experimentation of the University of Antioquia, 
Colombia, record No. 72. 
2.2 Type of Study
A prospective positive-controlled study with dogs ran-
domized to receive fenbendazole or secnidazole.
  2.3 Study Population and Treatment Protocols
This is a field study the owners maintained the dogs. Dogs 
eligible for inclusion in the study had owner consent as 
well as a positive test for Giardia cysts by fecal flotation 
with zinc sulfate solution on the day of examination. A 
total of 34 out of 250 clinically healthy dogs from the 
metropolitan area of Medellin met these criteria. The fol-
lowing hematological and biochemical parameters were 
analyzed on the day 0 of examination and at day 8 after 
treatment: complete blood count, BUN, creatinine, ALT, 
alkaline phosphatase, albumin, and direct and indirect 
bilirubin. Ten animals were excluded from the study due 
to concurrent illness, death, or being lost to follow-up. 
The study involved 24 dogs that were divided in 2 groups: 
secnidazole at 30 mg/kg PO single dose or fenbendazole 
at 50 mg/kg PO daily for 3 days. The secnidazole group 
was comprised of 4 females and 8 males with a mean age 
of 33 months (range 12–48 months).  The fenbendazole 
group included 7 females and 5 males, with a mean age of 
28 months (range 10–48 months).
2.4 Diagnostic Tests
Blood samples were collected on the day of examination 
(day 0) and at day 8 post-treatment.  Stool samples were 
collected on days 0, 8, 15, and 30 post-treatment.  The 
day of treatment (day 1), the perineal area was thoroughly 
bathed with a quaternary ammonium solution 0.05% to 
remove cysts from the hair coat and prevent reinfection 
from grooming. The owners were advised and trained to 
disinfect every day the premises where the dogs lived and 
to promptly remove feces to limit environmental contam-
ination.  They were also instructed to notify for any signs 
of vomiting, diarrhea, anorexia, or other abnormalities. 
The diagnostic tests for Giardia included a direct smear 
examination for cysts following centrifugal fecal flotation 
with zinc sulfate, and multiple ELISA for the detection of 
Giardia antigens in feces (SNAP Giardia Test, IDEXX 
Laboratories) [18]. The sample was considered infected 
when resulted positive at least in one test. Statistical anal-
ysis was performed using SAS software with chi square 
analysis for qualitative variables (positive or negative in-
fection) and Student’s t for quantitative variables, and the 
level of statistical significance was set at P<0.05.
3. Results
A total of 250 stool samples from a random population 
of dogs from Medellin were processed by fecal flotation 
with zinc sulfate to detect Giardia cysts.  There were 34 
positive samples, giving a prevalence of 13.6% of the 
studied population. Some of these animals had to be re-
moved from the study because they have clinical signs 
and a more complete treatment that included hydration, 
antibiotics and analgesics was required, leaving 24 suit-
able dogs that were equally divided in 2 groups to receive 
fenbendazole or secnidazole. This study did not include an 
untreated infected group, and effectiveness of treatment 
was determined by comparing the different evaluation 
days with day 0.
The number of positive and negative animals following 
treatment is shown in Table 1.  In the group of animals 
that received secnidazole, there were 4, 3, and 1 dogs pos-
itive on days 8, 15, and 30, respectively, being always the 
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same positive animals. In the fenbendazole group, only 
1 of 12 animals had Giardia cysts on day 8; however, 3 
dogs were positive at 15 days and the same 3 dogs were 
positive at 30 days after treatment. No statistical differ-
ences were observed in outcomes between the treatment 
groups (p>0.05). 
With regard to the hematological and biochemical 
parameters analyzed, all values were within the normal 
range in every animal before treatment and on day 8 after 
treatment (Tables 2, 3, and 4).  In addition, the owners did 
not report diarrhea or signs suggestive of adverse drug ef-
fects throughout the study period.
4. Discussion
Prevalence rates for Giardia infection in dogs have been 
reported to vary from 1% in fecal samples from well-man-
aged pets to 28% in shelter dogs [5,8,9,19,20].  Typically, 
younger animals may show signs of infection, with adults 
being subclinical carriers [5,19,21].  In this study, 34 out of 
250 (13.6%) dogs were positive by fecal flotation tech-
nique.  
The classical treatment used in dogs and cats against 
Giardia has been fenbendazole (50 mg/kg/day for 3–5 
days), and experimental infestations have shown its effi-
cacy close to or at 100% [11,12]. Those studies are in accor-
dance with the present results where only 1 of 12 animals 
was positive on day 8 following a 3-day treatment proto-
col with fenbendazole.  The fact that a total of 3 animals 
in the fenbendazole group tested positive on days 15 and 
30 suggests that re-infection occurred in 3 dogs.
Other studies have used alternative drugs with more 
variable results, including metronidazole at 30–50 mg/kg 
q12h for 15 days with or without silimarin [14], and alben-
dazole at 25 mg/kg q12h for 2 days [11]. Similar to the re-
sults of this study, these products have good effects on the 
control of Giardia in dogs, but none over 100% of treated 
canines at all assessment times.
Earlier studies in cats showed that a single oral dose of 
30 mg/kg secnidazol reached 100% efficacy at days 6, 7, 
and 8 post-treatment [17]. In this study, only 8 of 12 dogs 
were negative on day 8 post-treatment, even though all 
animals, except for one, turned negative by day 30.  It is 
possible that because of the intermittent nature of Giardia 
shedding (from undetectable to large concentrations in 
feces), the negative test results on day 30 coincided with 
a time of no shedding.  Therefore, infection cannot be de-
finitively ruled out in spite of the lack of cysts in the fecal 
samples.
The pharmacological treatment of Giardia infection in 
dogs and cats is very effective; however, there may appear 
cases of therapeutic failure, that are very likely due to re-
infection phenomena through the ingestion of cysts from 
the environment [22,23]. Reinfection is a phenomenon that 
in this study probably occurred since the animals were all 
the time in their homes with their owners and the disin-
fection was in charge of these, with possible flaws in this 
process. In addition, this study did not have information 
on the coexistence of other animals or humans that could 
be able to favor reinfection.
Thus, besides the antiprotozoal treatment, accompany-
ing measures such as post-treatment bath and sanitation of 
the environment have been recommended before consid-
ering resistance to treatment [23]. Therefore, in this study 
we used the combination of treatment with secnidazol or 
fenbendazol together with the disinfection of the quarters 
with quaternary ammonium and washing of the perineum 
of the study subjects, thus reducing the risk of recontam-
ination with the cysts excreted by the parasite. The high 
resistance and ubiquity of the Giardia cysts also play an 
important role in the recontamination. Nevertheless, our 
results indicate that treatment with secnidazol or fenben-
dazol, together with hygienic measures like disinfection 
with quaternary ammonium of patients and their environ-
ment, may be effective to eliminate the excretion of Giar-
dia cysts in canines. 
The administration of nitroimidazoles in animals may 
cause adverse reactions such as anorexia, nausea, and di-
arrhea [23] and a study reported that in felines secnidazol 
may cause increase of liver enzymes [17]. In the present 
study, none of the animals treated, that were asymptom-
atic, showed alterations or changes in their laboratory pa-
rameters. Nonetheless, more studies are suggested to help 
confirm drug´s safety mainly, if second doses of treatment 
are employed to counter reinfections.
Supplement
Table 1. Number of dogs shedding Giardia intestinalis 
cysts before and after treatment with secnidazole or fen-
bendazole
N° of positive animals/Total (%)*
Day 0 8 15 30
Secnidazole
30 mg/kg PO once
12/12
(100%)a
4/12
(33.3%)b
3/12
(25%)b
1/12
(8.3%)b
Fenbendazole
50 mg/kg PO for 3 
days
12/12
(100%)a
1/12
(8.3%)b
3/12
(25%)b
2/12
(25%b)
Note: *A positive animal was diagnosed based on detection of cysts by 
fecal centrifugation-flotation technique using zinc sulfate, and/or a posi-
tive ELISA result (SNAP Giardia Test, IDEXX Lab).
               a,b Numbers followed by different letters in each row are statisti-
cally different from each other (P<0.05). No differences were observed 
between groups at any given time.
DOI: https://doi.org/10.30564/vsr.v1i1.1067
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Table 2. Mean (±SD) of hematological parameters in dogs 
infected with Giardia intestinalis, before and after treat-
ment with secnidazole and fenbendazole
Parameter* Before treatment After treatment
Erythrocyte (x106/ul) Reference range (5.5-8.5)
Secnidazole 6.87 ± 1.06 6.91 ± 0.95
Fenbendazole 6.63 ± 0.81 6.68 ± 0.79
Hematocrit (%) Reference range (37-55)
Secnidazole 45.02 ± 7.22 45.50 ± 8.11
Fenbendazole 43.50 ± 5.93 42.11 ± 5.99
Hemoglobin (g/dl) Reference range (12-18)
Secnidazole 14.84 ± 2.32 14.93 ± 2.36
Fenbendazole 14.23 ± 2.28 13.72 ± 2.09
MCV (fl) Reference range (60-77)
Secnidazole 63.17 ± 2.08 62.33 ± 3.06
Fenbendazole 64.25 ± 3.41 63.83 ± 4.04
MCH (Pg) Reference range (21-27)
Secnidazole 22.14 ± 0.74 22.09 ± 0.94
Fenbendazole 21.68 ± 1.29 21.01 ± 1.17
MCHC (g/dl) Reference range (32-37)
Secnidazole 35.14 ± 0.99 34.99 ± 2.69
Fenbendazole 33.67 ± 1.38 32.81 ± 1.22
RDW (%) Reference range (12-16)
Secnidazole 14.85 ± 0.64 15.03 ± 0.94
Fenbendazole 15.32 ± 1.26 15.45 ± 1.51
Platelets (x103/ul) Reference range (190-500)
Secnidazole 195.33 ± 56.70 220.08 ± 87.35
Fenbendazole 252.58 ± 77.75 248.08 ± 72.33
Note: MCV: Mean Corpuscular Volume.
          MCH: Mean Corpuscular Hemoglobin.
          MCHC: Mean Corpuscular Hemoglobin Concentration.
          RDW: Red blood cell Distribution Width.
          *No statistical differences were observed among groups or before 
and after treatment.
Table 3. Mean (±SD) of white blood cells in dogs infected 
with Giardia intestinalis, before and after treatment with 
secnidazole and fenbendazole
Variable* Before treatment After treatment
Total leukocyte count (/ul)                     Reference range (100-1700)
Secnidazole 11385.83 ± 3513.78 11764.17 ± 3165.25
Fenbendazole 18095.00 ± 5569.51 14962.50 ± 5660.67
Eosinophils (/ul) Reference range (100-1700)
Secnidazole 1624.61 ± 1551.33 1582.78 ± 1400.74
Fenbendazole 1669.04 ± 935.04 1599.68 ± 1775.98
Neutrophils (/ul) Reference range (3300-12000)
Secnidazole 6113.69 ± 2834.44 6952.72 ± 2805.93
Fenbendazole 11982.08 ± 5245.06 9444.13 ± 3895.04
Bands (/ul) Reference range (0-300)
Secnidazole 224.05 ± 340.88 84.87 ± 186.14
Fenbendazole 184.73 ± 220.34 32.14 ± 82.22
Lymphocytes (/ul) Reference range (1000-4500)
Secnidazole 3070.91 ± 971.06 2848.98 ± 1232.76
Fenbendazole 3856.25 ± 1563.57 3474.21 ± 1020.68
Monocytes (/ul) Reference range (100-700)
Secnidazole 314.91 ± 296.98 278.91 ± 211.43
Fenbendazole 402.91 ± 296.87 412.38 ± 245.09
Note: * No statistical differences were observed among groups or before 
and after treatment.
Table 4. Mean (±SD) of some clinical biochemistry in 
dogs infected with Giardia intestinalis, before and after 
treatment with secnidazole and fenbendazole
Parameter* Before treat-ment After treatment
ALT(UI/l) Reference range (21-102)
Secnidazole 47.20 ± 34.91 36.45 ± 11.29
Fenbendazole 43.42 ± 31.11 36.25 ± 9.09
Alkaline phosphatase (UI/l)                   Reference range (10-73)
Secnidazole 40.00 ± 17.26 27.75 ± 15.74
Fenbendazole 61.25 ± 37.77 58.09 ± 33.32
BUN (mg/dl) Reference range (10-28)
Secnidazole 25.60 ± 4.41 29.13 ± 4.76
Fenbendazole 26.26 ±5 .20 24.16 ± 7.25
Creatinine (mg/dl) Reference range (0.5-1.5)
Secnidazole 1.03 ± 0.14 1.05 ± 0.18
Fenbendazole 0.87 ± 0.13 0.92 ± 0.17
Total protein (g/l)                Reference range (54-71)
Secnidazole 77.50 ± 12.48 79.50 ± 8.27
Fenbendazole 69.83 ± 5.56 69.33 ± 5.93
Albumin (g/l) Reference range (26-33)
Secnidazole 28.10 ± 4.56 28.08 ± 4.56
Fenbendazole 30.00 ± 3.77 31.58 ± 5.66
Total bilirubin (mg/dl)                       Reference range (0.1-0.9)
Secnidazole 0.72 ± 0.35 0.74 ± 0.55
Fenbendazole 0.94 ± 0.44 0.86 ± 0.71
Note: * No statistical differences were observed among groups or before 
and after treatment.
References
[1] Thompson RCA. The zoonotic significance and mo-
lecular epidemiology of Giardia and Giardiasis. Vet 
Parasitol, 2004, 126(1–2): 15–35.
[2] Arroyo-Salgado B, Buelvas-Montes Y, Villalba-Viz-
caíno V, Salomón-Arzuza O. Genetic profiling of 
DOI: https://doi.org/10.30564/vsr.v1i1.1067
28
Veterinary Science Research | Volume 01 | Issue 01 | June 2019
Distributed under creative commons license 4.0
Giardia intestinalis by polimerase chain in human 
and dogs samples of Colombian Caribean Coast. En-
ferm Infecc Microbiol Clin. 2013, 32(xx): 424–7. 
[3] Boeke CE, Mora-Plazas M, Forero Y, Villamor E. In-
testinal protozoan infections in relation to nutritional 
status and gastrointestinal morbidity in Colombian 
school children. J Trop Pediatr, 2010, 56(5): 299–
306. 
[4] Chaves M del P, Fernández JA, Ospina I, López MC, 
Moncada L, Reyes P. Giardia duodenalis prevalence 
and associated risk factors in preschool and school-
age children of rural Colombia. Biomedica, 2007, 
27(3): 345–51. 
[5] Hamnes IS, Gjerde BK, Robertson LJ. A longitudi-
nal study on the occurrence of Cryptosporidium and 
Giardia in dogs during their first year of life. Acta 
Vet Scand, 2007, 49: 22. 
[6] Papini R, Gorini G, Spaziani A, Cardini G. Survey on 
giardiosis in shelter dog populations. Vet Parasitol, 
2005, 128(3–4): 333–9. 
[7] Yoshiuchi R, Matsubayashi M, Kimata I, Furuya M, 
Tani H, Sasai K. Survey and molecular characteriza-
tion of Cryptosporidium and Giardia spp. in owned 
companion animal, dogs and cats, in Japan. Vet Para-
sitol, 2010, 174(3–4): 313–6. 
[8] Bajer A, Bednarska M, Rodo A. Risk factors and 
control of intestinal parasite infections in sled dogs in 
Poland. Vet Parasitol, 2011, 75(3–4): 343–50. 
[9] Soriano SV, Pierangeli NB, Roccia I, Bergagna HFJ, 
Lazzarini LE, Celescinco A, et al. A wide diversity of 
zoonotic intestinal parasites infects urban and rural 
dogs in Neuquén, Patagonia, Argentina. Vet Parasitol, 
2010, 167(1): 81–5. 
[10] Meireles P, Montiani-Ferreira F, Thomaz-Soccol V. 
Survey of giardiosis in household and shelter dogs 
from metropolitan areas of Curitiba, Paraná state, 
Southern Brazil. Vet Parasitol, 2008, 152(3–4): 242–
8. 
[11] Barr SC, Bowman DD, Heller RL. Efficacy of fen-
bendazole against Giardiasis in dogs. Am J Vet Res. 
1994, 55(7): 988–90.
[12] Keith CL, Radecki S V, Lappin MR. Evaluation of 
fenbendazole for treatment of Giardia infection in 
cats concurrently infected with Cryptosporidium par-
vum. Am J Vet Res. 2003, 64(8): 1027–9. 
[13] Löfmark S, Edlund C, Nord CE. Metronidazole is 
still the drug of choice for treatment of anaerobic in-
fections. Clin Infect Dis. 2010, 50 Suppl 1: S16-23. 
[14] Chon S-K, Kim N-S. Evaluation of silymarin in the 
treatment on asymptomatic Giardia infections in 
dogs. Parasitol Res. 2005, 97(6): 445–51. 
[15] Escobedo AA, Cimerman S. Giardiasis: a pharma-
cotherapy review. Expert Opin Pharmacother, 2007, 
8(12): 1885–902. 
[16] Gardner TB, Hill DR. Treatment of Giardiasis. Clin 
Microbiol Rev. 2001, 14(1): 114–28. 
[17] Da Silva AS, Castro VSP, Tonin A a., Brendler S, 
Costa MM, Jaques J a., et al. Secnidazole for the 
treatment of Giardiasis in naturally infected cats. 
Parasitol Int. Elsevier Ireland Ltd. 2011, 60(4): 429–
32. 
[18] Costa M, Clarke C, Mitchell S, Papasouliotis K. Di-
agnostic accuracy of two point-of-care kits for the di-
agnosis of Giardia species infection in dogs. J Small 
Anim Pract, 2016, 57(6): 318–22. 
[19] Bouzid M, Halai K, Jeffreys D, Hunter PR. The 
prevalence of Giardia infection in dogs and cats, a 
systematic review and meta-analysis of prevalence 
studies from stool samples. Vet Parasitol, 2015, 
207(3–4): 181–202. 
[20] Torres-Chablé OM, García-Herrera RA, Hernán-
dez-Hernández M, Peralta-Torres JA, Ojeda-Robertos 
NF, Blitvich BJ, et al. Prevalence of gastrointestinal 
parasites in domestic dogs in Tabasco, southeastern 
Mexico. Rev Bras Parasitol veterinária, 2015, 24(4): 
432–7. 
[21] Alves J, Santos A. Prevalence of Giardia spp. in 
young dogs using a combination of two diagnostic 
methods. Acta Parasitol / Witold Stefański Inst Para-
sitol Warszawa, Pol. 2016, 61(2): 261–6. 
[22] Fiechter, R., Deplazes, P., Schnyder, M. Control of 
Giardia infections with ronidazole and intensive hy-
giene management in a dog kennel. Veterinary para-
sitology, 2012, 187: 93-98.
[23] Payne, P.A., Artzer, M., The biology and control of 
Giardia spp and Tritrichomonas foetus. The Veteri-
nary clinics of North America, 2009, 39: 993-1007.
DOI: https://doi.org/10.30564/vsr.v1i1.1067
